TNFRSF1B（TNF receptor superfamily member 1b）為TNF受體超家族成員，也稱為TNFR2，主要表達在腫瘤微環(huán)境中的Treg細胞和多種腫瘤細胞中（如卵巢癌和腸癌）。TNFR2與受體TNF結(jié)合后，通過激活典型和非典型的NF-kB通路來控制細胞的生存和增殖。大量研究顯示，TNFR2抑制劑能夠特異性抑制在腫瘤微環(huán)境中高表達TNFR2的Tregs的功能，同時特異性殺傷腫瘤細胞，用于抗腫瘤治療；而TNFR2激活劑則可以激活Tregs細胞，抑制效應性T細胞（Teff），進而下調(diào)免疫反應，可以用于自身免疫疾病治療。隨著對于新靶點的不斷深入挖掘，TNFR2的重要性日漸受到關(guān)。TNFR2已經(jīng)成為免疫逃逸、腫瘤生長以及檢查點阻斷抵抗性的潛在誘因。TNFR2抑制劑抗體則能夠抑制腫瘤相關(guān)Tregs的增殖和功能。

Recombinant Human TNFRSF1B 活性蛋白實驗驗證數(shù)據(jù)

High Purity Validated
by SDS-PAGE

(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Excellent Bioactivity Validated by Functional ELISA

Measured by its binding ability in a functional ELISA. Immobilized TNF-α (CSB-YP023955HU) at 5 μg/ml can bind human TNFR2, the EC₅₀ of human TNFR2 protein is 1.162-1.481 ng/ml.

Excellent Bioactivity Validated by Functional ELISA

Measured by its binding ability in a functional ELISA. Immobilized LTA (CSB-MP013218HU) at 5 μg/ml can bind human TNFRSF1B, the EC₅₀ is 1.632-2.699 ng/ml.